Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)Ciara Louise Freeman, Krina K. Patel, Shinsuke Iida et al.|Blood|2025Cited by 1
OA-08 Safety and Preliminary Efficacy of BMS-986393, a GPRC5D CAR T Cell Therapy, in Patients (pts) With Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Results From a Phase 1 StudyMyo Htut, Susan Bal, Omar Nadeem et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 0